Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Fractyl Health, Inc.. The associated price target is $10.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Ulz has given his Buy rating due to a combination of factors that highlight Fractyl Health, Inc.’s promising developments and strategic focus. The company’s Revita treatment is on track to demonstrate significant weight loss maintenance, with expectations that it will outperform typical outcomes seen with Tirzepatide withdrawal. This potential to achieve less than 3% weight regain, coupled with a strong safety profile, positions Revita as a potentially groundbreaking treatment in the weight management sector.
Furthermore, Fractyl’s recent data from the Germany Real-World Registry study supports Revita’s long-term efficacy, showing notable weight loss and HbA1c reduction without serious adverse events. The advancement of their Rejuva gene therapy program and an extended cash runway into 2026 further bolster the company’s prospects. These elements collectively suggest a positive outlook for Fractyl Health, Inc., justifying the Buy rating.
Ulz covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Ulz has an average return of -4.0% and a 38.77% success rate on recommended stocks.